微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 5.3% | 22.69% | 162.38% | 58/159 | 1.2% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-06-30 | 2.02% | -25.74% | 25.47% | 82/159 | 0.26% | 翰宇药业 | 18.95% | 行业排名> |
| 2025-03-31 | 1.61% | 21.05% | -67.34% | 67/159 | -0.37% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-12-31 | 4.93% | 10.79% | 14.12% | 59/159 | -9.52% | 百利天恒 | 181.27% | 行业排名> |
| 2024-09-30 | 4.32% | -14.46% | 58.82% | 68/159 | 4.23% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | 2.72% | -10.82% | 104.51% | 67/159 | 2.66% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | 1.33% | -38.71% | -70.11% | 81/159 | 2.32% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | 4.45% | -52.61% | -11.88% | 67/159 | -1.03% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 5.05% | -17.08% | 65.57% | 69/159 | 2.34% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | 3.05% | -37.11% | 40.55% | 67/159 | 1.46% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 2.17% | 83.9% | -76.89% | 57/159 | 1.37% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | 9.39% | 9.44% | 54.19% | 46/159 | 0.67% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 6.09% | -35.21% | 25.57% | 56/159 | 2.8% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 4.85% | 15.48% | 311.02% | 47/159 | 2.16% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 1.18% | -48.02% | -86.25% | 85/159 | 1.57% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 8.58% | 6.72% | -8.72% | 50/159 | 0.75% | 人福医药 | 6.82% | 行业排名> |
| 2021-09-30 | 9.4% | 25% | 123.81% | 36/159 | 4.43% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 4.2% | 4.48% | 85.02% | 67/159 | 2.94% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 2.27% | 25.41% | -71.77% | 62/159 | 2.49% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | 8.04% | 3.47% | 6.91% | 68/159 | 3.58% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | 7.52% | 4.3% | 87.06% | 52/159 | 3.03% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | 4.02% | -2.43% | 122.1% | 65/159 | 4.19% | 河化股份 | 45.32% | 行业排名> |
| 2020-03-31 | 1.81% | -27.89% | -76.71% | 52/159 | 2.19% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | 7.77% | -1.89% | 7.77% | 71/159 | 2.53% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 7.21% | -9.88% | 75% | 49/159 | 7.48% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 4.12% | -12.53% | 64.14% | 60/159 | 4.96% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 2.51% | -13.45% | -68.31% | 43/159 | 2.41% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 7.92% | -18.94% | -1% | 67/159 | 6.99% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 8% | -21.95% | 69.85% | 39/159 | 7.18% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 4.71% | -15.89% | 62.41% | 45/159 | 4.6% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 2.9% | -12.12% | -70.32% | 32/159 | 2.54% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 9.77% | -8.09% | -4.68% | 50/159 | 9.61% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 10.25% | -10.64% | 83.04% | 27/159 | 8.29% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 5.6% | -7.28% | 69.7% | 36/159 | 5.58% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 3.3% | -3.51% | -68.96% | 21/159 | 2.09% | 河化股份 | 54.24% | 行业排名> |
| 2016-12-31 | 10.63% | 11.08% | -7.32% | 51/159 | 6.19% | 华东医药 | 7.2% | 行业排名> |
| 2016-09-30 | 11.47% | 3.71% | 89.9% | 20/159 | 5.61% | 南新制药 | 81.7% | 行业排名> |
| 2016-06-30 | 6.04% | 19.13% | 76.61% | 33/159 | 3.48% | 德展健康 | 29.5% | 行业排名> |
| 2016-03-31 | 3.42% | 9.27% | -64.26% | 21/159 | 2.65% | 贝达药业 | 16.78% | 行业排名> |
| 2015-12-31 | 9.57% | 13.52% | -13.47% | 51/159 | 11.27% | 河化股份 | 19.29% | 行业排名> |
| 2015-09-30 | 11.06% | 17.29% | 118.15% | 20/159 | 7.22% | 一品红 | 58.17% | 行业排名> |
| 2015-06-30 | 5.07% | 16.02% | 61.98% | 35/159 | 4.87% | 华东医药 | 36.97% | 行业排名> |
| 2015-03-31 | 3.13% | 17.23% | -62.87% | 27/159 | 2.41% | 华东医药 | 26.63% | 行业排名> |